Roche has signed a global collaboration worth up to $1.7 billion with cancer drugs firm Blueprint Medicines based around pralsetinib, a drug that targets tumours with RET mutations.

Abstract: High-voltage vertical regrown p-n junction diodes on bulk GaN substrates are reported in this letter with molecular-beam-epitaxy regrown p-GaN on metalorganic-chemical-vapor-deposition grown ...

The Swiss government has given the go-ahead for the sale of 71 Leopard 1 A5 tanks belonging to the Swiss company RUAG MRO to Germany but has barred its further transfer to Ukraine. "The Federal ...